



Patient portrayal.
For adults only.

MS, multiple sclerosis.

*Once monthly after 3 weekly starter doses.

Important Safety Information

Who should not take KESIMPTA?

Do NOT take KESIMPTA if you:

- Have an active hepatitis B virus (HBV) infection.
- Have had an allergic reaction to ofatumumab or life-threatening injection-related reaction to KESIMPTA.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).



Kesimpta[®]
(ofatumumab) 20 mg
injection

For Relapsing MS



"I chose KESIMPTA® as my first treatment—it fits with my busy life, and I was impressed by the results.*"

—Andy M.

EXPLORE WHAT'S INSIDE

Check out the study results*	Page 4
See how the auto-injector pen works	Page 6
Discover how KESIMPTA can fit your lifestyle	Page 7
Learn how KESIMPTA targets B-cells	Page 10
Understand the safety profile	Page 12
Considerations in B-cell treatments	Page 16
Hear from others taking KESIMPTA	Page 18
Explore the support available	Page 20

Unless otherwise indicated, everyone in this guide lives with relapsing MS, has taken KESIMPTA, and has been compensated for their time.

Important Safety Information (cont)

What is the most important information I should know about KESIMPTA?

KESIMPTA can cause serious side effects such as:

- **Infections.** Serious infections, which can be life-threatening or cause death, can happen during treatment with KESIMPTA. If you have an active infection, your health care provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting



"I'm not letting relapsing MS disrupt my life."

—Caylee R.

TAKE CONTROL OF YOUR TREATMENT CHOICE

With KESIMPTA, you have the power to decide where you get your treatment on your treatment day. KESIMPTA is the only B-cell treatment for RMS that you take **once a month**[†] from the comfort of home, or bring it with you. No infusion days required.



PROVEN RESULTS*



PROVEN SAFETY PROFILE*,
plus an ongoing safety study[‡]



EASY-TO-USE[§]
PREFILLED PEN

*In 2 studies vs teriflunomide.

[†]Once monthly after 3 weekly starter doses.

[‡]Based on an ongoing extension study. See full details on [page 12](#).

[§]As seen in a real-world, 30-question survey of 105 patients (aged ≥18) diagnosed with RMS for 1+ years, who took KESIMPTA with the auto-injector pen within the previous 12 months. See full details on [page 8](#).

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**
(ofatumumab) 20 mg injection

POWERFUL RESULTS WITH KESIMPTA

Over 1800 people with relapsing MS participated in **2 head-to-head studies comparing KESIMPTA® to teriflunomide**. In the 1 to 2 years leading up to the studies, all of them had experienced a relapse or saw activity on an MRI scan.

PROVEN SUPERIOR

 **Reducing Relapses**

 **Fewer Lesions**

 **Slowing Disability Progression**

	STUDY 1 vs teriflunomide	STUDY 2 vs teriflunomide
RELAPSES	51% fewer relapses	58% fewer relapses
ACTIVE LESIONS (Gd+ T1)	98% fewer lesions 0.01 for KESIMPTA vs 0.46 for teriflunomide on average per MRI scan	94% fewer lesions 0.03 for KESIMPTA vs 0.52 for teriflunomide on average per MRI scan
NEW OR ENLARGING LESIONS (T2)	82% fewer lesions 0.72 for KESIMPTA vs 4.00 for teriflunomide per year	85% fewer lesions 0.64 for KESIMPTA vs 4.16 for teriflunomide per year
DISABILITY PROGRESSION	Studies 1 & 2 combined 34% less likely at 3 months* 32% less likely at 6 months*	

Gd+, gadolinium-enhancing; MRI, magnetic resonance imaging.
*Based on whether disability progression was still present 3 and 6 months after disability symptoms started.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).



"I'm glad I chose KESIMPTA, but after seeing the results first-hand, I wish I had started sooner."

— Jamie Lynn Sigler
Mom, Actor, MS Advocate
Started KESIMPTA in 2023

CUT RELAPSES BY MORE THAN HALF, AND REDUCED ACTIVE LESIONS BY OVER 90%[†]

Individual results may vary.
[†]As shown in 2 studies vs teriflunomide.

Important Safety Information (cont)

- infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.
- HBV reactivation.** If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.

PEN FEATURES THAT HELP YOU DO IT RIGHT

The KESIMPTA® auto-injector pen is designed to help you **use it safely, right from the comfort of home**, once a month.* Someone from your health care team will show you how to use it first so you'll be ready on treatment day.

1 YOU CAN'T SEE THE NEEDLE

- It's thinner than a pediatric needle†
- It goes just under skin, not into muscle
- Just press pen against skin to start

2 IT GUIDES YOU WITH SOUNDS

- You'll hear 1 click when it starts
- You'll hear a 2nd click when it's almost done

3 AND YOU CAN SEE THE PROGRESS

- Watch as the window fills with **green**
- It stops moving when complete
- Ensure the **green** progress indicator fills the window and stops moving before removing the pen



HOW KESIMPTA CAN FIT INTO YOUR LIFE

KESIMPTA allows you to take control of your treatment by putting it in your hands—literally.

Take it yourself **once a month**,* giving you the flexibility you need to work with your busy life.



KESIMPTA COMES TO YOU

The pen is delivered right to your door, prefilled, and **ready to go** when you are.‡



TREATMENT ON YOUR TERMS

You can take KESIMPTA **wherever works best for you**§ on your treatment day. There's **no pretreatment with steroids**|| or infusion days required.



IT'S TRAVEL FRIENDLY

If you're traveling on treatment day, don't worry. **The pen can be kept at room temp for up to 7 days**,§ so you can take it with you.



[Click to see](#) how to use the pen, step-by-step.

*Once monthly after 3 weekly starter doses.

†KESIMPTA pens come with a staked needle of 29-gauge. Pediatric needles average between 23-gauge and 25-gauge.

‡Take the KESIMPTA pen out of the refrigerator 15 to 30 minutes before injecting to allow it to reach room temperature.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**
(ofatumumab) 20 mg injection

§KESIMPTA pens must be refrigerated at 2 °C to 8 °C (36 °F to 46 °F). Keep product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake. If necessary, KESIMPTA may be stored at room temperature below 30 °C (86 °F) for up to 7 days and returned to the refrigerator, to be used within the next 7 days. If not used within those 7 days, discard the medicine.

||Limited benefit of premedication with corticosteroids, antihistamines or acetaminophen seen in RMS studies.

Important Safety Information (cont)

- **Progressive Multifocal Leukoencephalopathy (PML).** PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include

THE KESIMPTA PEN IS EASY TO USE

In a real-world survey,* people described their experience with the auto-injector pen. **Here's what they had to say:**

~90%

Found the pen
easy to use
and said monthly
dosing was
convenient.

In a separate
survey,†

9/10 Nurses
and
8/10 Patients
preferred the
pen's features.



*Real-world, 30-question survey of 105 US patients (aged ≥18) diagnosed with RMS for 1+ years, who took KESIMPTA® with the auto-injector pen within previous 12 months. On a scale of 1-5, 89.5% of patients rated it a 4 or 5 (5 being most positive) on overall ease of use and ease of monthly dosing schedule. Questionnaire not validated.

†Based on a survey of MS nurses (N=50) and patients (N=80) in the US, Germany, France, and Italy. Participants were asked to compare attributes of the KESIMPTA auto-injector pen with those of other disease modifying therapy (DMT) auto-injectors, some of which are not available in the US. The KESIMPTA pen was not injected during the survey, nor were all devices compared against each other by participants. A total of 17 attributes were assessed, with "easy to perform self-injection with the pen," "ease of preparation and set-up," and "ease of training patient in use" among those most preferred.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta®**
(ofatumumab) 20 mg
injection

"I was a little
intimidated by
the pen, until I
used it for the first time.
Now, I'm good to go."

—Maggie B.



[Click to watch](#) the KESIMPTA
Crew share what they love
most about the pen.

Important Safety Information (cont)

weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.

- **Weakened immune system.** KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.

ROLE OF B-CELLS IN RELAPSING MS

To understand how KESIMPTA® works, it's important to know how B-cells and relapsing MS are connected.



B-cells

B-cells are part of the immune system that helps fight infections. They are found throughout the body.



RMS-related B-cells

In RMS, immune cells, such as B-cells, located in the lymph nodes, are mistakenly sent to attack the body's myelin—the protective covering around the nerves in the brain and spinal cord.


For illustrative purposes only.

KESIMPTA IS PRECISELY DELIVERED

While it's not fully understood how KESIMPTA works, it's designed to target the B-cells in the lymph nodes believed to play a role in RMS.

Think of your body like a maze:

- As a subcutaneous injection just under the skin, KESIMPTA is thought to target a **precise path to RMS-related B-cells** in the lymph nodes*
- This targeted delivery is thought to **limit the impact on other B-cells** your body needs to maintain immune function



For illustrative purposes only.
*Based on preclinical studies.

Important Safety Information (cont)

Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:

- Have or think you have an infection including HBV or PML.
- Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.



[Click to watch](#) Candice explain the science behind KESIMPTA.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).



PROVEN SAFETY PROFILE

Before you start any treatment, it's important to understand the safety profile and possible side effects.

KESIMPTA® was studied in 2 head-to-head studies vs teriflunomide.



Few people stopped treatment due to side effects

(comparable to teriflunomide: 5.7% for KESIMPTA, 5.2% for teriflunomide)



Mild to moderate injection-related reactions

99.8% of injection-related reactions were mild to moderate. They were most common in the 1st injection and decreased to less than 3% after the 3rd dose



KESIMPTA has a proven safety profile, and has been studied for 8 years and counting.

Because safety is so important, KESIMPTA continues to be studied in an ongoing, open-label* extension study.†

"Once I learned more about KESIMPTA and its safety profile, I became a whole lot more confident moving forward."

—Angie B.

*A type of study where participants are aware of the type of treatment they're being given. Interpreting results from open-label studies can be uncertain. They are not considered representative results, since participants chose whether to stay in the trial.

†After the original KESIMPTA studies, over 1700 people continued to participate for further evaluation, where they all took KESIMPTA. The goal of this extended study was to learn about the safety and tolerability of KESIMPTA in the long term, with a focus on injection-related reactions, malignancies, and serious infections for up to 8 years. No conclusions of clinical outcomes can be drawn. (September 25, 2025 data cut-off date.)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta®**
(ofatumumab) 20 mg injection

Important Safety Information (cont)

- Have a history of liver problems.
- Have had a recent vaccination or are scheduled to receive any vaccinations.
 - You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive 'live' or 'live-attenuated' vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.

POSSIBLE SIDE EFFECTS

KESIMPTA® could increase the risk of serious, including life-threatening or fatal, infections:

Hepatitis B virus (HBV) reactivation: Before starting KESIMPTA, you'll get a blood test for HBV. If you've ever had HBV infection, it may become active again during or after treatment with KESIMPTA.

Progressive multifocal leukoencephalopathy (PML): PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks, and can result in death or severe disability. While no cases of PML were reported in RMS clinical trials with KESIMPTA, it could happen.

Other serious side effects are:

- **Local injection-site reactions:**

Symptoms include redness, pain, itching, and swelling.

- **Injection-related reactions:**

Symptoms include fever, headache, pain in the muscles, chills, tiredness, rash, hives, trouble breathing, swelling of the face, eyelids, lips, mouth, tongue and throat, and feeling faint, or chest tightness.

- **Low immunoglobulins:**

KESIMPTA may decrease some types of antibodies.

- **Liver damage:**

B-cell therapies, including KESIMPTA, may cause liver damage. Symptoms may include yellowing of the skin and eyes, nausea, vomiting, unusual darkness of urine, and feeling tired or weak.

Your doctor will do blood tests to check your immunoglobulin levels and liver before you start KESIMPTA and while you take it, if needed.

HERE'S WHAT'S MOST COMMON

- **Upper respiratory tract infections**

Symptoms include sore throat, runny nose, and headache.

- **Headache**

Before you take KESIMPTA, tell your doctor if you have any infections. It's also important to tell your doctor if you:

- Have or think you have HBV or PML
- Have taken or plan to take medication that affects your immune system
- Have a history of liver problems
- Had a recent vaccination or have one scheduled
- Are pregnant, think you may be, or are planning to be
- Are breastfeeding or plan to

[Click to review](#) the full Medication Guide.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**
(ofatumumab) 20 mg injection

CHOOSING YOUR RMS TREATMENT

Each B-cell treatment* comes with different requirements to take them, and they all factor into what your treatment day might look like.

Things to Consider

KESIMPTA®	Take it yourself	Take it at home or bring with you	No pretreatment with steroids [†]	No post-dose observation
Other B-cell treatments*	Administered by a health care provider	Mainly taken in a medical facility, travel required	Pretreatment with steroids required [‡]	Post-dose observation

 **Be sure to share your preferences and ask your doctor what's involved to find the treatment that fits your lifestyle.**

Steps for injecting KESIMPTA[§]:

- Remove from fridge 15-30 mins to get to room temp
- Visually inspect for expiration date and liquid clarity
- Choose and clean the injection site
- Twist off cap only when ready to use. Discard cap, use within 5 mins
- Press firmly against skin at 90°. After the second click, the green indicator will stop moving. Remove pen
- Dispose in an FDA-cleared sharps container

Important Safety Information (cont)

- Whenever possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with KESIMPTA.
- Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.

YOUR TIME. YOUR TREATMENT. YOUR CHOICE.

Administration Times & Methods*

KESIMPTA®		<1 min auto-injection (3-4 secs avg injection time)	1x monthly[†] at home or on the go
Ocrevus® (ocrelizumab)		2-4 hrs infusion	2x yearly mainly at a medical facility
Ocrevus Zunovo® (ocrelizumab and hyaluronidase-ocsq)		10 mins injection	2x yearly mainly at a medical facility
Briumvi® (ublituximab-xiiy)		1-4 hrs[#] infusion	2x yearly at a medical facility

This is not a complete list of all the available treatments for RMS.*
The comparison pertains only to differences in dosing and administration and should not be considered a comparison of efficacy or safety.

[Click to see](#) what your dosing schedule could look like with KESIMPTA.

*B-cell treatments for RMS include: KESIMPTA, Ocrevus (ocrelizumab), Ocrevus Zunovo® (ocrelizumab and hyaluronidase-ocsq), and Briumvi (ublituximab-xiiy). Please see each product's respective prescribing information for additional information, including indication, dosing, administration, and safety. Trademarks are the property of their respective owners.

[†]Limited benefit of premedication with corticosteroids, antihistamines, or acetaminophen seen in RMS studies.

[‡]Other B-cell treatments require premedications 30-60 minutes before starting treatment to reduce risk of reactions.

[§]These are not the full Instructions for Use (IFU). Please see IFU for more information.

^{||}Typical administration time when ready to inject.

[†]Once monthly after 3 weekly starter doses.

[#]The 1st infusion of Briumvi takes 4 hrs. Subsequent infusions take 1 hr.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).



THE KESIMPTA CREW IS HERE FOR YOU

More and more people are making their choice to treat with KESIMPTA® and join the Crew. Whenever you're ready, you've got their support.



"MS can be invisible. We're here to help make it so **you don't feel invisible.**"

Andy M.

Dad,
Account Executive

"The important thing is not to give up. **You can take charge—we got you!**"

Jamie Lynn Sigler

Mom, Actor,
MS Advocate

"We love sharing our different experiences to **help you navigate yours.**"

Kamryn R.

Mom,
Entrepreneur

"We all need a support network and **we can be part of yours.**"

Zenavia W.

Entrepreneur,
Wellness Coach

"As people living with RMS, **we've been there and learned a lot along the way.**"

Caylee R.

Volleyball Coach,
Favorite Aunt

"Like you, we each have unique stories, **but we all found our fit with KESIMPTA.**"

Luis G.

Dad,
Composer

"RMS comes with a lot of questions. **We're here to help you find the answers.**"

Angie B.

Mom,
Jewelry Business Owner

Important Safety Information (cont)

- Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after your last treatment. Talk with your HCP about what birth control method is right for you during this time.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

The KESIMPTA Crew is speaking up about their first-hand experiences with:

[Being your own advocate](#)



[Juggling family, work, and dating with RMS](#)



[Deciding on KESIMPTA](#)



And more!

[YouTube.com/@KESIMPTA](https://www.youtube.com/@KESIMPTA)

Click to watch their stories on YouTube™:

Kesimpta
(ofatumumab) 20 mg injection

SUPPORT AVAILABLE TO YOU

A KESIMPTA® prescription comes with membership to Novartis Patient Support™. You'll get access to:

- ✓ **Getting Started** – Coordinating medication delivery.
- ✓ **Financial Support** – If you are privately insured, you could pay as little as **[\$0]** on KESIMPTA with Co-Pay Plus.
- ✓ **Co-pay assistance** – **96%** of all prescriptions filled have a **[\$0] out-of-pocket** cost when used with the Co-Pay Plus offer.*†
- ✓ **Ongoing support** – Dedicated support throughout your treatment.
- ✓ **Helpful resources** – like step-by-step videos and more.

*Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance who are initially denied coverage may receive free KESIMPTA for up to **[15]** doses while seeking coverage. Patients with commercial insurance who have coverage for KESIMPTA may receive up to **[\$18,000]** in annual co-pay benefits. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at [\[start.kesimpta.com\]](https://start.kesimpta.com).

†2025 data on file.

Important Safety Information (cont)

- Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

EASY TO GET STARTED

Have a KESIMPTA prescription but aren't a member yet?
It's easy to get started.



To speak to a Novartis Patient Support team member, call

855-KESIMPTA (855-537-4678), Monday-Friday, 8:30 AM–8:00 PM ET, excluding holidays.

- Press option 2 for insurance and financial support
- Press option 3 for ongoing support

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).



Indication

What is KESIMPTA® (ofatumumab) injection?

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.

It is not known if KESIMPTA is safe or effective in children.

Important Safety Information

Who should not take KESIMPTA?

Do NOT take KESIMPTA if you:

- Have an active hepatitis B virus (HBV) infection.
- Have had an allergic reaction to ofatumumab or life-threatening injection-related reaction to KESIMPTA.

What is the most important information I should know about KESIMPTA?

KESIMPTA can cause serious side effects such as:

- **Infections.** Serious infections, which can be life-threatening or cause death, can happen during treatment with KESIMPTA. If you have an active infection, your health care provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.
- **HBV reactivation.** If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.

Important Safety Information (cont)

- **Progressive Multifocal Leukoencephalopathy (PML).** PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.
- **Weakened immune system.** KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.

Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:

- Have or think you have an infection including HBV or PML.
- Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.
- Have a history of liver problems.
- Have had a recent vaccination or are scheduled to receive any vaccinations.
 - You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive 'live' or 'live-attenuated' vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.
 - Whenever possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with KESIMPTA.
 - Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**
(ofatumumab) 20 mg
injection

Important Safety Information (cont)

- Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA® will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after your last treatment. Talk with your HCP about what birth control method is right for you during this time.
- Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use KESIMPTA?

See the detailed Instructions for Use that comes with KESIMPTA for information about how to prepare and inject a dose of KESIMPTA and how to properly throw away (dispose of) used KESIMPTA Sensoready® pens or prefilled syringes.

- Use KESIMPTA exactly as your HCP tells you to use it.
- Your HCP will show you how to prepare and inject KESIMPTA the right way before you use it for the first time.
- **Do not** inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks.

KESIMPTA may cause serious side effects including:

- **Injection-related reactions.** Injection-related reactions are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later injections. There are two kinds of reactions:
 - **At or near the injection site:** redness of the skin, swelling, itching, and pain. Talk to your HCP if you have any of these signs and symptoms.

Important Safety Information (cont)

- **That may happen when certain substances are released in your body:** fever, headache, pain in the muscles, chills, tiredness, rash, hives, trouble breathing, swelling of the face, eyelids, lips, mouth, tongue and throat, and feeling faint, or chest tightness. Contact your HCP right away if you experience any of these signs and symptoms, especially if they become worse or you have new severe signs of reactions after subsequent injections. It could be a sign of an allergic reaction, which can be serious.
- **Low immunoglobulins.** KESIMPTA may cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood immunoglobulin levels.
- **Liver damage.** KESIMPTA may cause liver damage. Your HCP will do blood tests to check your liver before you start KESIMPTA and while you take KESIMPTA if needed. Tell your HCP right away if you have any symptoms of liver damage such as:
 - yellowing of the skin and eyes (jaundice)
 - nausea
 - vomiting
 - unusual darkening of the urine
 - feeling tired or weak

The most common side effects of KESIMPTA include:

- Upper respiratory tract infection, with symptoms such as sore throat and runny nose, and headache.
- Headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

 **Kesimpta**
(ofatumumab) 20 mg injection



GET PREPARED TO ASK ALL THE RIGHT QUESTIONS WITH THE KESIMPTA CREW

It's okay if you're feeling unsure about where to start. The KESIMPTA® Crew has been there too. They asked their doctors the important questions and put what they learned into a **Decision Guide to help you talk treatment with your doctor.**

[Click to download](#) the RMS Treatment Decision Guide

"It was a big decision.
But after my doctor
answered my questions,
**I felt confident
choosing KESIMPTA.**"

—Kaila A.

For adults only.

KESIMPTA.com/[sign-up](#)

 [YouTube.com/@KESIMPTA](#)

Please see full Important Safety Information throughout this brochure. Click here for full [Prescribing Information](#) including [Medication Guide](#).

All trademarks are the property of their respective owners.

 **Kesimpta**®
(ofatumumab) 20 mg
injection

For Relapsing MS

 **NOVARTIS**

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2026 Novartis

8/26

FA-11666728